Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

8 Items

per page
  1. Nilotinib(AMN-107)
    A8232 Nilotinib(AMN-107)
     1 Citation
    Target: Bcr-Abl
    Summary: Bcr-Abl kinase inhibitor,selective
      ≥26.5 mg/mL
  2. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  3. CP-724714
    A2412 CP-724714
    Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R
    Summary: HER2 inhibitor,potent and selective
      ≥23.5 mg/mL
  4. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  5. PP121
    B2172 PP121
    Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck
    Summary: Dual inhibitor of tyrosine and phosphoinositide kinases
  6. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL
  7. Radotinib(IY-5511)
    B5846 Radotinib(IY-5511)
    Target: PDGFR|Bcr-Abl
    Summary: Bcr-Abl tyrosine kinase inhibitor
      ≥13.73 mg/mL
  8. Imatinib (STI571)
    B2171 Imatinib (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Protein-tyrosine kinase inhibitor
      ≥24.68 mg/mL

8 Items

per page